A compound of Formula (II-g): or a pharmaceutically acceptable salt thereof; wherein: R b is methyl; R 1 is selected from (C 1 -C 4 alkyl)-O, spirooxirane, cyano, =O, nitro, (C 1 -C 4 alkyl)C(O), and HO(C 1 -C 4 alkyl)C(O); R 2 is =O, H, or OR a , where R a is selected from H, optionally substituted C 1 -C 4 alkyl, or optionally substituted aryl, with the proviso that when R 2 is =O, R 8 is not present; R x is =O or OR d , where R d is H or C(O)R e , where R e is optionally substituted C 1 -C 22 alkyl or optionally substituted C 2 -C 22 alkenyl, with the proviso that when R x is OH, it is in the beta configuration and when R x is R d , with R d being C(O)R e , then it is preferably in the beta configuration; R 4 is independently selected from H and unsubstituted C 1 -C 4 alkyl; R 6 is H, optionally substituted C 1 -C 4 alkyl, or optionally substituted C 1 -C 4 alkoxy; R 7 is H, optionally substituted C 1 -C 4 alkoxy, or an optionally substituted morpholinyl ring; R 8 , when present, is H or optionally substituted C 1 -C 4 alkyl; - - - denotes an optional, additional C-C bond, resulting in either a C=C bond between C 4 -C 5 or C 5 -C 6 , with the proviso that when present, the C 5 -H substituent is not present; and, - - - denotes an optional, additional C-C bond, resulting in a C=C bond between C 16 -C 17 , with the proviso that: (i) when R x is =O, a C=C bond is present between C 4 -C 5 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and CH 3 C(O)-; and (ii) when R x is beta-OH, a C=C bond is present between C 5 -C 6 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and HOCH 2 C(O)-. R b is methyl; R 1 is selected from (C 1 -C 4 alkyl)-O, spirooxirane, cyano, =O, nitro, (C 1 -C 4 alkyl)C(O), and HO(C 1 -C 4 alkyl)C(O); R 2 is =O, H, or OR a , where R a is selected from H, optionally substituted C 1 -C 4 alkyl, or optionally substituted aryl, with the proviso that when R 2 is =O, R 8 is not present; R x is =O or OR d , where R d is H or C(O)R e , where R e is optionally substituted C 1 -C 22 alkyl or optionally substituted C 2 -C 22 alkenyl, with the proviso that when R x is OH, it is in the beta configuration and when R x is R d , with R d being C(O)R e , then it is preferably in the beta configuration; R 4 is independently selected from H and unsubstituted C 1 -C 4 alkyl; R 6 is H, optionally substituted C 1 -C 4 alkyl, or optionally substituted C 1 -C 4 alkoxy; R 7 is H, optionally substituted C 1 -C 4 alkoxy, or an optionally substituted morpholinyl ring; R 8 , when present, is H or optionally substituted C 1 -C 4 alkyl; - - - denotes an optional, additional C-C bond, resulting in either a C=C bond between C 4 -C 5 or C 5 -C 6 , with the proviso that when present, the C 5 -H substituent is not present; and, - - - denotes an optional, additional C-C bond, resulting in a C=C bond between C 16 -C 17 , with the proviso that: (i) when R x is =O, a C=C bond is present between C 4 -C 5 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and CH 3 C(O)-; and (ii) when R x is beta-OH, a C=C bond is present between C 5 -C 6 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and HOCH 2 C(O)-. (i) when R x is =O, a C=C bond is present between C 4 -C 5 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and CH 3 C(O)-; and (ii) when R x is beta-OH, a C=C bond is present between C 5 -C 6 , then R 1 is selected from methoxy, spirooxirane, cyano, nitro, and HOCH 2 C(O)-. <EOS>